Government Tightens Rules After Child Deaths Linked to the Contaminated Cough Syrups
Now, buying a cough syrup in India will no longer be the same. In a major regulatory move that is aimed at improving the safety of medicines, the Union Ministry of Health and Family Welfare has revised the Drug Rules, making a doctor’s prescription mandatory for the sale of oral liquid medicinal cough syrups across the country.
This decision is taken after a series of tragic incidents involving contaminated cough syrups and growing concerns over the misuse of these medicines. Health experts believe that this move will help improve patient safety and ensure that cough-related illnesses are properly diagnosed before the treatment begins
Why has the government changed the rules?
This change in the Drug rules is due to the case linked to contaminated cough syrups, which led to the death of 24 children in Madhya Pradesh and Rajasthan. Investigations found that the presence of Diethylene Glycol (DEG), a highly toxic industrial contaminant, far exceeded the permissible safety limit of 0.1% in certain cough syrup formulations.
The authorities found these and had already banned three cough syrups named Coldrif, Respifresh TR, and ReLife.
This latest amendment is another step taken towards strengthening India’s drug safety framework and preventing similar incidents in the future.
According to the Ministry, the revised rule is intended to improve the regulatory oversight of the syrup formulations while ensuring better public health standards.
What exactly has changed?
The Ministry has amended the Drugs Rules, 1945, by removing the word “syrup” from Schedule K, which allowed the cough syrups to be sold in villages with a population below 1000 without a prior physician consultation.
With this exemption removed:
- A valid doctor’s prescription will now be required to buy oral liquid medicinal syrups, including cough syrup
- Cough syrups can only be dispensed through licensed pharmacies
- Retailers and distributors must strictly comply with the provisions of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945.
This change is aimed at ensuring that these medicines are sold only under the proper medical supervision.
Why are Experts Supporting this Decision?
Pulmonologists and public health experts have largely supported this amendment, as many cough syrups contain ingredients such as codeine or Dextromethorphan, which may cause drowsiness, interact with other medicines, and be misused if taken without medical advice.
Doctors also point out that a persistent cough may indicate an underlying condition like asthma, allergies, pneumonia, or other respiratory infections, and restricting the OTC sales will make patients seek medical evaluation instead of self-medicating.
This decision is also expected to reduce the misuse and abuse of cough syrups, especially among teenagers and young adults.
Part of a Bigger Push for Drug Safety
This is not the first time India has tightened the regulations around cough medicines. Even last year, the government prohibited the use of fixed-dose combinations that contain Chlorpheniramine maleate and Phenylephrine Hydrochloride in children below four years of age. The move aligned India with countries like the United States, Canada, and the United Kingdom, where similar restrictions already exist.
India has also introduced stricter quality testing and manufacturing standards that follow international concerns over the contaminated cough syrups that are exported to countries like the Gambia and others.
Conclusion
The government’s decision to make cough syrups prescription-only marks an important shift in India’s approach to medicine safety. It might be inconvenient for some patients, but this move is expected to control the misuse and improve the treatment outcome, while helping prevent the future tragedies that are linked to unsafe or improperly used cough medicines.
